Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company: Theranexus & Pherecydes-Pharma POCs
  • 2016: PRESS-RELEASE: Paris October 4, 2016: Theranexus, a CEA Life Sciences' spin-off exploiting CEA/BMSystems' copatent WO/2010/029131, obtained an orphan drug designation from the FDA for THN102, (in Phase II)  in the treatment of narcolepsy.Download  official Theranexus' press-relase

  • 2016: ANNOUNCEMENT: Paris October 5, 2016: BMSystems' CEO invited to present its digital-biology strategy and achievements at the inaugural session of Medicen Paris Region 10th years anniversary

  • 2016: PRESS RELEASE: Paris September 5, 2016: BMSystems selected to present CADI Discovery at the Connexion R&D conference organized by COSMETIC-VALLEY the leading Perfumery & Cosmetic cluster in France.

  • 2016: ANNOUNCEMENT August 1, 2016: BIO-MODELING SYSTEMS' novel Parkinson's therapy mentioned in a Report Covering 179 Companies. A new recognition of CADI Discovery capability to generate novel therapeutic strategies in complex human diseases of which CNS
  • 2016: ANNOUNCEMENT : May 31, 2016: Theranexus, CEA Life Sciences' spin-off exploiting CEA/BMSystems' copatent WO/2010/029131, in CNS therapies in Biotech Info (page 11)

  • 2016: PRESS-RELEASE: May 17, 2016; Theranexus, CEA Life Sciences' spin-off exploiting CEA/BMSystems' copatent WO/2010/029131, in CNS therapies, announced it reaches its primary endpoint in the proof of concept trial of THN102 in Excessive Daytime Sleepiness (EDS) A major result for the company that validates for the first time in man its approach of combining a CNS drug with a glial connexin modulator.

  • 2016: ANNOUNCEMENT: May 9, 2016: CMC-Strategy Forum Europe. Manuel GEA Chairman Adebiotech and CEO BMSystems invited to present French biotech / Bioproduction Competitiveness and BMSystems' best practices. download

  • 2016: PRESS-RELEASE Paris march 30, 2016:  Theranexus, CEA Life Sciences' spin-off exploiting CEA/BMSystems' copatent WO/2010/029131, in CNS therapies, announced Preclinical results published in the specialist medical journal Sleep and the Phase II entry of its combined drug THN102

  • 2016: ANNOUNCEMENT: Februray 12, 2016 Berlin: BMSystems invited to the Conference "IP in Life Sciences Digital Health" to present CADI Discovery answers to big data issues and biases in scientific publications

  • 2015: PRESS-RELEASE New-York October 27-28 2015: The Galien Foundation selects BMSystems for the MedStartUp Award program first step during the US Galien Prize Forum in New-York.This event brings together top cutting-edge companies where innovation, scientific excellence and creative commercial goals are of utmost importance. Download the pitch

  • 2015: Inaugural Presentation Bio-Entrepreneur 2015: The future will be digital and biology, but who will lead? Google? Watson? Alone or MDs, Physiologists, Biologists educating and mastering them combining diagnostics, therapies, connected devices and IT technologies?

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology company that delivers

Correct understanding of life mechanisms makes novel integrated diagnostics, therapies & preventive solutions discovery smarter, faster & cheaper for healthcare, diagnostic, health technologies, nutrition, and cosmetics!

Bio-Modeling Systems is the world’s first Mechanisms-Based medicine company that changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™ Discovery models.

Created in 2004, profitable since 2006, thanks to our recurrent clients, our patented collaborative discoveries already led to:

  1. A world's first in neurodegenerative diseases (publication) with CEA: 2 awards in the US & Europe

  1. Pherecydes-Pharma: BMSystems' spin-off, MR infections therapies,  publication, world's first clinical trial with phages in Phase I/II,

  2. Theranexus: CEA Life Sciences' spin-off exploiting  CEA/BMSystems' copatent  WO/2010/029131, in CNS therapies,  Phase II entry,  ODD from FDA

We warmly invite you to download our  6 pages management summary,  our Short corporate Presentation or our Full Presentation with all non confidential details our 9 POCs in details.

The life-modeling issue


BMSystems’ solutions to critical & high impact R&D and business issues

Invented and operated by our Biologists, CADI™* Discovery is, since 2004, the world's first and only to date operational "Mechanisms-based Medicine" platform that proposes:

  1. robust decision making support for R&D and Business, and

  2. the discovery of cost-effective lower risk patentable novel integrated solutions,

*CADI™ : Computer Assisted Deductive Integration